Trial Profile
Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Belinostat (Primary) ; Busulfan (Primary) ; Gemcitabine (Primary) ; Melphalan (Primary) ; Rituximab (Primary) ; Filgrastim; Glutamine; Pyridoxine; Pyridoxine
- Indications Burkitt's lymphoma; Diffuse large B cell lymphoma; Hodgkin's disease; Precursor cell lymphoblastic leukaemia-lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 03 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Mar 2016 New trial record